

## Technology Advisory Committee A Interests Register

### Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 to 17 [ID5104]

Publication Date: 29 May 2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dominic Pivonka	Committee A Member	Personal interests	Dominic has a former colleague who is UK Head of Market Access for the submitting company (Novartis)	22/02/2024	It was agreed that Dominic's declaration would not prevent him from participating in discussions on this appraisal.
Lynley Marshall	Clinical Expert	Direct – financial	Member of independent data monitoring committees for two paediatric clinical trials run by Merck and Eisai (honoraria received) – outside of the context of BRAF or MEK inhibitors.	12/03/2024	It was agreed that Lynley's declaration would not prevent her from participating in discussions on this appraisal.